Background. Plasma levels of several chemokines and cytokines were evaluated in a cohort of 161 human immunodeficiency virus (HIV)-positive patients to shed light on a clinically relevant mechanism that would explain the putative beneficial effect of GB virus type C (GBV-C) coinfection.
fection [7] [8] [9] [10] [11] [12] . Recently, reduced levels of HIV replication associated with GBV-C infection have been associated with the induction of HIV-inhibitory chemokines, such as CCL5, in an ex vivo cell culture model [13] . However, the mechanisms underlying this interaction are unknown, and it is unclear whether it may play a role in a clinical context.
It is well known that b-chemokines and cytokines play a central role in the evolution of HIV disease [14, 15] . CCL5 has been shown to enhance or inhibit HIV replication in vitro at different stages of the viral life cycle [16, 17] . CCL5 has also been reported to prevent infection due to macrophage-tropic, non-syncitiuminducing (NSI) variants of HIV in cell culture, by binding to the CCR5 [18] . Stromal cell-derived factor 1 (CXCL12) was reported to block the replication of virus isolates that use the CXC chemokine receptor 4 (CXCR4). Syncitium-inducing (SI) variants and CXCR4-using (X4) variants appear late in HIV infection and are associated with a more rapid decrease in the CD4 + T cell count [19, 20] . Cytokines such as IL-7, which is essential for regulating T cell homeostasis [21] , are known to enhance HIV replication [22, 23] and have been associated with the evolution of X4 strains [24] . Previous studies have found a possible association between levels of IL-7 and CXCL12 in plasma and the progression of HIV infection. It has been hypothesized that these cytokines might be considered as possible markers of disease progression [24, 25] . Collectively, these data underscore the complex roles that chemokines play in HIV infection. However, their exact role in the progression of the disease is still largely unclear.
To better understand the role that GBV-C infection may play in modulating the progression of HIV disease, we hypothesized that the presence of GBV-C may alter the expression pattern of various cytokines reported to be important for the HIV life cycle, hampering HIV replication and therefore delaying progression of the disease. To test this hypothesis, we performed a cross-sectional study to evaluate a possible relationship between the presence of GBV-C and b-chemokine and cytokine levels in plasma in a cohort of 161 patients with HIV infection.
MATERIALS AND METHODS

Patients
Plasma from blood samples collected between September 1994 and September 1996 from the 161 HIV-positive patients enrolled in this study was isolated after centrifugation of samples at 1250 g for 10 min in a Centra-GP8 IEC centrifuge (Hucoa) and was immediately cryopreserved and stored at Ϫ80ЊC until use. Immunological and virological studies were performed in 2001 and 2003, respectively, with PBMCs isolated on the same day and from the same blood sample used to obtain the blood plasma. Signed informed consent was obtained from each patient. Fifty-six of 161 patients were enrolled in clinical trials to receive monotherapy with either zidovudine or dideoxyinosine, and 99 patients were enrolled in clinical trials to receive dualdrug therapy with zidovudine plus dideoxycytosine, zidovudine plus dideoxyinosine, or zidovudine plus lamivudine; these patients later received triple-antiretroviral therapy. Six patients had never received antiretroviral therapy at the time of sample collection. The samples used in this study were those corresponding to the baseline sample obtained before enrollment in an antiretroviral clinical study. The immunological, virological, and epidemiological variables of the complete cohort of patients are shown in table 1.
Laboratory Analyses
GBV-C markers. For detection of GBV-C RNA, reverse-transcription and nested PCR were performed as described elsewhere, with use of primers directed at the 5 -noncoding region [26] . Serum anti-E2 antibodies were detected in GBV-C RNAnegative patients with use of an immunoassay using recombinant E2 (Anti-HGenv Enzymun test; Roche Molecular Systems) according to the manufacturer's instructions.
Virologic and immunologic markers of HIV infection. HIV RNA levels in plasma were determined using a commercial assay (Amplicor HIV Monitor Assay; Roche Molecular Systems) according to the manufacturer's instructions. CD4 + and CD8 + lymphocyte counts were determined with specific monoclonal antibodies by fluorescence-activated cell sorting (FACSCalibur; Becton Dickinson).
Determination of chemokine and cytokine levels in plasma samples. Plasma IL-7, CCL5, and CXCL12 levels were determined as described elsewhere [25, 27] . TNF-a levels were measured with use of a commercial ELISA (Endogen).
Viral isolation and phenotype in MT-2 cells. PBMCs ( cells) obtained from HIV-infected individuals were 6 10 ϫ 10 cocultured with PBMCs ( cells) obtained from healthy 6 5 ϫ 10 donors and stimulated with 3 mg of phytohemagglutinin per mL and 25 IU of IL-2 per mL. Viral replication was monitored by evaluation of HIV antigen p24 production in coculture supernatants with use of a commercial ELISA (Innogenetics). Cocultured supernatants that had results positive for p24 were collected after centrifugation at 400 g for 5 min, and the SI or NSI phenotype was determined in MT-2 cells as described elsewhere [28] . In brief, cells were infected with 50 mL of 3 5 ϫ 10 virus stock; 5 days after infection, cells were observed for syncitium formation and presence of detectable of p24 antigen at 1/1000 dilution. For simplicity, individuals from whom SI or NSI variants were isolated are hereafter referred to as "SI subjects" or "NSI subjects," respectively. 
Statistical
RESULTS
Characteristics of the cohort of HIV-infected subjects.
The epidemiological, immunological, and virological characteristics of the patients in the study are summarized in table 1. GBV-C RNA was detected in 44 (27%) of 161 patients, and anti-E2 antibodies were found in 19 (21%) of 87, consistent with the findings of previous reports [5, 29] . The distribution of GBV-C markers was similar with respect to age, sex, and risk factors for HIV infection. As described elsewhere [6, 29] , individuals with detectable GBV-C RNA had significantly lower median HIV loads in plasma and significantly higher CD4 + and 
NOTE.
Only the values that reached statistical significance are indicated. CBP, contaminated blood product; CXCL12, stromal cell-derived factor 1; GBV-C, GB virus type C; IDU, injection drug use; IND, indeterminate risk factor; MSM, men who have sex with men; NSI group, subjects with non-syncitiuminducing strains of GB virus; SI group, subjects with syncitium-inducing strains of GB virus.
a Estimated length of HIV infection at time of presentation. b Presence of anti-hepatitis C virus (HCV) antibodies, by EIA. c for GBV-C RNA-positive subjects versus GBV-C anti-E2-positive subjects and subjects with no markers for GBV-C infection. P ! .006 d for GBV-C RNA-positive subjects versus GBV-C anti-E2-positive subjects and subjects with no markers for GBV-C infection. NOTE. Only those subsets that reached statistical significance are indicated for each group of patients. NSI group, subjects with non-syncitiuminducing strains of GB virus; SI group, subjects with syncitium-inducing strains of GB virus. a for patients in the SI group coinfected with GBV-C versus patients in the SI group not coinfected with GBV-C. P ! .005
CD8
+ T cell counts than did individuals with no markers for GBV-C infection or with past GBV-C infection (table 1) .
Relationship between GBV-C and chemokine and cytokine levels in plasma. As shown in table 1, GBV-C infection status did not influence the plasma levels of IL-7, CCL5, CXCL12, and TNF-a in the study cohort. As described elsewhere [24] , patients who harbored SI virus strains showed significantly higher IL-7 levels that did those who harbored NSI virus strains ( ). Similarly, TNF-a and CCL5 levels were higher in P p .005 SI subjects than in NSI subjects ( and , re-P ! .001 P p .0035 spectively) (table 1 and figure 1). When patients were grouped according to the phenotype of the infecting HIV strain, the levels of IL-7, CCL5, CXCL12, and TNF-a did not appear to be significantly altered either by the concurrent infection with for GBV-C RNA-positive patients versus GBV-C RNA-negative patients. GBV-C or by the presence or absence of anti-E2 antibodies ( figure 1, table 1 , and data not shown).
GBV-C infection status of patients grouped by the phenotype of the HIV-infecting strain.
No statistically significant differences were observed between the SI and NSI groups in terms of age, sex, and risk factors for HIV infection. As we have described elsewhere [24, 25] , CD4 + T cell and CD8 + T cell counts and viral load were significantly different between both groups of patients, suggesting a more advanced stage of the disease in the SI group (table 1) . Notably, GBV-C viremia was less prevalent in SI subjects than in NSI subjects (13 ). However, no differences were P p .6 observed in the overall clearance rates of GBV-C infection between SI and NSI groups of patients (10 [20%] of 49 and 9 [23%] of 38;
). As shown in table 2, among SI sub-P p 1.000 jects, only those who showed ongoing GBV-C replication had CD4 + T cell counts that were statistically higher than those in the group of SI subjects who showed either clearance or no markers for GBV-C infection. However, this difference in CD4 + T cell counts was not observed between the group of patients coinfected with NSI and the groups of patients with anti-E2 antibodies or with no markers for GBV-C infection (table 2) .
Characteristics of the cohort of patients according to the CD4 + T cell count. Because HIV disease may progress in the absence of the SI variants, it was important to compare individuals in the SI group with those in the NSI group who were in a similar stage of disease. To this end, we stratified the patients of both groups according to the CD4 + T cell count (with a cutoff value of 200 cells/mL). No significant differences in the levels of IL-7, CXCL12, CCL5, or TNF-a were found to be associated with the presence of GBV-C RNA, the presence of anti-E2 antibodies, having no markers for GBV-C infection, or having an SI strain or an NSI strain in either subset of CD4 + T cell count values (data not shown). As shown in table 3, GBV-C viremia was strongly associated with higher CD4 + T cell counts in the subset of symptomatic patients with р200 CD4 + T cells/mL, irrespective of the HIV-infecting strain, whereas this difference in CD4 + T cell counts was not observed in the subset of patients with 1200 CD4 + T cells/mL. It is of interest that, when patients were grouped according to the phenotype of the HIV-infecting strain, only that group of SI subjects coinfected with GBV-C and belonging to the lower subset of CD4 + T cell counts showed significantly higher CD4 + T cell counts than those found in the group of SI subjects not coinfected with GBV-C (table 3) .
DISCUSSION
This study investigated the effect of detectable GBV-C viremia on b-chemokine and cytokine levels in a large population of HIV-coinfected patients. The frequency of detection of GBV-C RNA and anti-E2 antibodies in this HIV-infected population was 27% and 21%, respectively, consistent with the findings of previous reports [5, 29] . An important finding of this study is that the detection of GBV-C RNA in plasma samples was not associated with a number of factors known or hypothesized to be related to HIV disease progression, such as elevated levels of CCL5, CXCL12, IL-7, and TNF-a. Likewise, no differences were observed in the levels of these chemokines and cytokines in plasma according to whether the patient had an SI or an NSI strain with or without coinfection with GBV-C, nor were differences observed when patients were grouped according to their CD4 + T cell counts. This is in contrast to the findings of a recent study from Xiang et al. [13] in which they observed a GBV-C-related induction of CCL5 and other chemokines in ex vivo cell culture. Such an increase was reported to be related to the observed inhibitory effect of GBV-C in HIV replication in this system. In our large cohort of patients, we did not observe any influence of the presence or absence of GBV-C on the plasma chemokine levels analyzed here in a clinically relevant context. Measuring the expression of chemokines in the blood may be an imprecise determination of what occurs in the tissues, where actual viral replication occurs. Nevertheless, the observation that other infectious agents, such as herpesvirus 6 in ex vivo lymphoid tissue [30] and Mycobacterium tuberculosis [31] in bronchoalveolar lavage cells, led to increased bchemokine production that is not associated with delays in the progression of HIV disease strongly argues against the protective role of pathogen-induced CCR5 ligands in vivo and may be in conflict with the observed effect of CCR5 ligands on HIV replication in cell culture [13] . Moreover, the observations that influenza virus induce type I interferons and that other unidentified soluble factors block R5 and X4 HIV replication [32] suggest alternative explanations for the protective effect of GBV-C infection in HIV-coinfected individuals that remain to be resolved. It is possible that, unlike in ex vivo studies, immunological and virological factors may be affecting these chemokine levels in clinical samples. IL-7, for instance, has been reported to influence CCL5 levels [27] . However, it is of note that, in the present work, we did not observe a correlation between the presence or absence of GBV-C viremia and IL-7 plasma levels. Both GBV-C and IL-7 are factors that have been correlated with disease progression. The latter has been associated with selection for and increased levels of X4 virus replication [24, 33, 34] . Our results show that GBV-C does not appear to influence IL-7 levels in this cohort of patients. In fact, when CD4 + T cell counts are taken into consideration in the analysis, the levels of IL-7 seem to be paralleling the CD4 + T cell counts irrespective of the presence or absence of GBV-C. It is possible that the correlation between CD4 + T cell counts and IL-7 levels might explain this phenomenon, pointing to a bystander character of GBV-C, as suggested elsewhere [7] . Over the past several years, in vivo interactions between GBV-C and HIV have been the subject of considerable puzzlement. A number of studies have linked this association to a more favorable prognosis [6, 8, 9, 12] . Other studies, however, have not shown such a survival advantage [7, 10, 11] . GBV-C status and time after HIV seroconversion appear to be important in whether the putative protective effects associated with GBV-C coinfection are observed [35, 36] and may account for the contradictory results reported so far.
However, in keeping with the findings of previous reports, GBV-C viremic patients in our study presented with higher CD4 + T cell counts than did patients who were not infected with GBV-C [6, 8, 9, 12] . It is of interest that our results also showed a strong association between GBV-C viremia and higher CD4 + T cell counts in patients who were immunocompromised. Namely, patients harboring SI strains or with р200 CD4 + T cells/mL presented with significantly higher CD4 + T cell counts than did their counterparts without coinfection. This finding is consistent with the findings of a previous report in which a substantial survival benefit was observed in patients with symptomatic disease [7] . It is, however, intriguing that this association was not observed in asymptomatic patients or patients harboring NSI strains. The meaning of this observation is unknown, but it may suggest that GBV-C viremia is associated with an undefined immune status for the patients with coinfection. This could be compatible with the hypothesis of immunological interference exerted by GBV-C suggested by others [37] or, alternatively, with GBV-C acting as a surrogate marker of a thus-far-uncharacterized immune status of a subset of patients.
Finally, we have found that SI subjects are less frequently infected with GBV-C than are NSI subjects. A possible explanation could be that in advanced stages of HIV disease, when HIV loads tend to be increased [38] , GBV-C replication might be suppressed [8] , hampering GBV-C RNA detection [7] . On the other hand, a relatively intact immune system might be required to sustain effective GBV-C replication [7, 39] . However, we have not observed differences in the rate of anti-E2 antibodies between SI subjects and NSI subjects (data not shown). Alternatively, GBV-C infection may prevent coinfected patients from progressing into a more advanced stage of the disease, which would imply a more active role of GBV-C in HIV disease progression. Because GBV-C and HIV can infect and replicate within PBMCs (mainly CD4 + T cells), this would be consistent with the hypothesis that GBV-C and HIV may interfere with each other's life cycle, as suggested by ex vivo studies [9, 13, 40] , or consistent with the hypothesis that a protective effect is exerted by specific GBV-C strains [36] . However, it is plausible that this subset of patients with GBV-C viremia had lower HIV loads-and, therefore, also slower clinical progression of the disease-than their counterparts without coinfection. Nonetheless, it remains to be elucidated why this particular subset of patients would have a diminished rate of HIV replication.
Our observational study does not allow us to assign a function to GBV-C. However, the findings of this study clearly show that GBV-C viremia was not associated with any altered expression pattern of the cytokines and chemokines analyzed that would explain a delayed progression of the disease in these patients. Alternative explanations for the protective effect of GBV-C infection in HIV-coinfected individuals via the increased levels of HIV-inhibitory chemokines remain to be resolved.
